Galecto, Inc.

NasdaqCM GLTO

Galecto, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024

Galecto, Inc. Return on Equity (ROE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Galecto, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -95.10%, a -46.50% change year over year.
Galecto, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -64.91%, a -91.51% change year over year.
Galecto, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -33.90%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqCM: GLTO

Galecto, Inc.

CEO	Dr. Hans T. Schambye M.D., Ph.D.
IPO Date	Oct. 29, 2020
Location	United States
Headquarters	75 State Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Key trends

Past 5 years